Analysts' Actions: BIIB FSLR GOOG LNKD

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Biogen Idec ( BIIB) was upgraded at Canaccord Genuity to buy. $187 price target. Expect an early launch for TEC, Canaccord Genuity said.

CoreSite Realty ( COR) was upgraded to buy at TheStreet Ratings.

Darden ( DHI) was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $50 price target. Commitment to raise dividend trumps lower guidance, BofA/Merrill said.

DigitalGlobe ( DGI) was upgraded to buy at TheStreet Ratings.

First Cash Financial Services ( FCFS) was downgraded at Jefferies to hold from buy. Downgrading to hold on valuation, Jefferies said.

First Solar ( FSLR) was downgraded at Robert Baird from outperform to neutral. $25 price target. Management has limited near-term visibility, Robert Baird said.

First Solar was downgraded at Bank of America/Merrill Lynch to underperform from buy. $25 price target. Solid results, disappointing outlook.

Google ( GOOG) was upgraded at Bank of America/Merrill Lynch to buy. $920 price target. Expect the company to expand margins in the coming quarters, BofA/Merrill said.

GrafTech International ( GTI) was downgraded at Goldman Sachs to sell from neutral. $5.50 price target. Worsening electrode oversupply structural issue, Goldman said.

Graftech was downgraded at J.P. Morgan to neutral. The company lacks earnings leverage, J.P. Morgan said.

Invensense ( INVN) was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $13 price target, Baird said.

Lincoln National ( LNC) was upgraded at Bank of America/Merrill Lynch. $34 price target. Company has the lowest multiple in the industry, BofA/Merrill said.

LinkedIn ( LNKD) was initiated with a buy rating at Wunderlich. $195 price target. Company has a large competitive advantage and solid revenue visibility, Wunderlich said.

Allscripts ( MDRX) was upgraded at Credit Suisse from neutral to outperform. $15 price target. New management can stabilize the business, Credit Suisse said.

Norwegian Cruise Line ( NCLH) was initiated with a neutral rating at Goldman Sachs. $28 price target. Best in class, but valuation on an even keel, Goldman said.

Norwegian Cruise ( NCLH) was initiated with an overweight rating at J.P. Morgan. $36 price target. Company can continue to increase price and yields, J.P. Morgan said.

Oceaneering ( OII) was upgraded at Sterne Agee from neutral to buy. $75 price target. Company can generate robust earnings and cash flow over the next several years, Sterne Agee said.

Verisign ( VRSN) was downgraded at Credit Suisse from outperform to neutral. $42.50 price target. Risk/reward is more balanced at current levels, Credit Suisse said.

Bio-Rad Laboratories ( BIO) target was raised at Jefferies. Shares are now seen reaching $140. Strong fourth-quarter result, Jefferies said. Buy rating.

Darden Restaurants ( DRI) numbers were lowered at Jefferies. Shares are now seen reaching $42. Estimates were also lowered on analyst meeting preannouncement, Jefferies said. Hold rating.

Expeditors International ( EXPD) numbers were lowered at Jefferies. Shares are now seen reaching $44. Estimates were also lowered on earnings miss, Jefferies said. Buy rating.

Home Depot ( HD) numbers were raised at UBS. Shares are now seen reaching $75. Estimates were also increased on strong execution, market share gains and good sector backdrop, UBS said. Buy rating.

Home Depot numbers were raised at Jefferies. Shares are now seen reaching $64. Estimates were also raised on share gains widening in the fourth quarter. Hold rating.

JPMorgan ( JPM) estimates, price target were raised at BofA/Merrill. Shares are now seen reaching $55, according to Bank of America/Merrill Lynch. Estimates were also increased, as the company should see better net interest income and reserve releases, BofA/Merrill said. Buy rating.

Macy's ( M) estimates were raised at UBS. Guidance points to accelerating FCF and expanding ROIC story. Neutral rating.

Priceline.com ( PCLN) estimates, target were boosted at Benchmark. Shares are now seen reaching $800. Estimates were also increased, given accelerating international growth, Benchmark said. Buy rating.

Priceline.com target was raised at Jefferies. Shares are now seen reaching $820. Another solid quarter with some accelerating trends, Jefferies said. Buy rating.

Questcor Pharmaceuticals ( QCOR) numbers were raised at Jefferies. Shares are now seen reaching $38. Estimates were also raised on strong fourth quarter with robust 2013 outlook, Jefferies said. Buy rating.

Vitamin Shoppe ( VSI) numbers were reduced at Credit Suisse. Shares are now seen reaching $65. Estimates were also cut, as the company is facing cost headwinds, Credit Suisse said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Worth a Stunning $6.6 Trillion, Tech Stocks Have Taken Over the Market

Worth a Stunning $6.6 Trillion, Tech Stocks Have Taken Over the Market

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Here's Why Snap Shares Climbed Monday

Here's Why Snap Shares Climbed Monday